Full-Time

Sales Excellence and Commercial Operations IT Project Manager

Posted on 11/23/2025

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Madrid, Spain

In Person

Category
IT & Security (1)
Business & Strategy (1)
Requirements
  • Bachelor's degree or equivalent
  • Information Technology, Computer Science Engineering Diploma
  • Commercial, Sales Excellence Courses/Experience
  • Advanced level of English
  • 5+ years of proven experience on delivering business and technical requirements in Commercial solutions and Technologies, elicitation, modeling, methodology development
  • Demonstrated IT project management skills - planning, organizing, and managing resources
  • Strong communication skills and ability to translate between commercial/technical terms and user terms
  • Assertiveness to influence
  • Experience in a large multinational and dynamic environment
  • Experience in applying industry standard business analysis approaches
  • Curiosity and willingness to learn, effective communication and ability to quickly develop new technical and functional competencies
  • Ability to work both independently and as a member of a team, earning the trust of customers and teammates
Responsibilities
  • Establish as a point of contact and accountability for IT Sales Excellence and Commercial Operations, leading exciting and strategic Sales Excellence and Commercial projects within the EU
  • Understands Commercial Customers operational needs and strategic direction, specifically in relation to Sales Operations, Analytics, Reports and Forecasting (Regional and Local perspective)
  • Analyzes business requirements and translates them into optimizing Sales operation activities and/or best solutions proposal: high value technology solutions, sales operation improvement and optimization, KPIs reports and defined dashboards
  • Identifies opportunities where technology can build competitive advantage in terms of Sales Operations and provide game-changing innovative ways of approaching key business questions
  • In collaboration with Business Project Manager and SMEs, prepares Project IT business case and presents it for project approval, manages new requirements and scope changes, according to IT governance
  • Define and design Sales Excellence and Commercial solutions, that meet client requirements expectations, designed to fulfill information to support strategic decision making and answer clear business questions, supporting strategic decision making
  • Build trust and solid work relationships with Customers and Business Stakeholders by establishing clear objectives and specific requirements and delivering on these according to plan, cost and quality, ensuring they are communicated regularly regarding progress achieved
  • Manages and sets stakeholder expectations, and ensures business unit sponsorship endorsement and agreements from corresponding SMEs
  • Ensures resources for projects, project ownership and project leadership from IT perspective. Define the RFQ and SOW for external vendors across the solutions delivery lifecycle
  • Works with service providers and customers to deliver solutions/projects according to established requirements
  • Maintain project plans/milestones and project activities against these. Manages project along with Business Project Owner and according to LT expectations. Manages requirements, project plans, phases, and ensures quality deliverables. Works with service providers and customers to deliver solutions/projects accordingly
  • Maintains flexibility, simplicity and future strategy and Technology Roadmap as pillars for decision making towards solution definition and design. Leverages solutions across countries
  • Ensures all aspects of Commercial Operations are considered through project activities to guarantee successful results
  • Provide all aspects of technical project management, including project scope, detailed project requirement definition, rigorous project estimates (including project plans, budget, timelines, and resourcing), clear decision gates, vendor SOWs, entrance/ exit criteria across phases of development, team resource management, metrics tracking, and technical program delivery to scope and quality standards
  • Effectively lead meetings with clients, vendors, and stakeholders, and conduct productive technology project team status/review meetings, and status reports communications
  • Perform business and functional analysis activities (e.g., documenting functional requirements) for projects as required
  • Identify, manage and bring to resolution project risks/ issues. Escalate major project risks to scope or budget or timeline to appropriate escalation points
  • Ensure smooth transition of production applications to support and maintenance structures working with Infrastructure, Security, Compliance, and Run and Support Teams
  • Review projects when complete against business case to ensure projected benefits are being realized
  • Key metrics for performance include on-time, on-budget, on-quality project delivery; client satisfaction on a project-to-project basis; user satisfaction and effective leadership of teams through influence
Desired Qualifications
  • Experience in the pharmaceutical industry

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hits $3.52B, up 8.1%, driven by Greater China demand.
  • Projects 5-6% revenue CAGR through 2030 with $11B cash for deployments.
  • UBS upgrades to Buy with $18 target on Inpefa launches and cost savings.

What critics are saying

  • FDA Indore warning letter slashes stock 15% on February 27, 2025.
  • Pfizer biosimilar captures 35% EU Lipitor share, cutting $1.2B sales.
  • FTC probes Mylan pay-for-delay deals, imposing $2B fine by 2028.

What makes Viatris unique

  • Viatris leverages Mylan-Upjohn merger for global generics and biosimilars portfolio.
  • Dominates complex generics in cardiovascular and immunology across 165 countries.
  • Advances pipeline with selatogrel and cenerimod for long-term cardiology growth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.

INACTIVE